Venture
capital valuations for start-up companies bear no similarity to share
valuations for profitable businesses, a concept apparently misunderstood by a
consortium of doctors who lost their investment in Ecolibrium Biologicals and
then tried unsuccessfully to claim more than twice the value of their original
investment from company directors after Ecolibrium was wound up insolvent.
Ecolibrium
Biologicals Holdings Ltd was the brainchild of microbiologist Stephen Ford. Based at Bombay in South Auckland, it looked
to commercialise use of biological rather than chemical pesticides.
This venture
eventually failed, the death-knell being receivership initiated by Mr Ford as secured
creditor.
Ecolibrium’s
assets were sold in 2022 to newly incorporated Cellora Ltd, with Mr Ford as minority
shareholder. Ecolibrium shareholders
received nothing.
During
Ecolibrium’s start-up phase, a consortium of doctors led by Mitul Jesani agreed
to put in seed capital. For Dr Jesani
personally, this was an initial investment in 2018 of $500,000 giving her what
was then a ten per cent shareholding.
Consortium
members were later required to tip in further cash, typically as short term
loans; some of which were converted to equity on terms that were never
specifically agreed, the High Court was told.
Evidence
was given off increasing tension between Ecolibrium management and the
consortium as the company burned through cash.
Short term loans were advanced to meet monthly bills, primarily wages.
Consortium
members were not willing to front up with a large sum as part of further
capital raising, but at the same time were against dilution of their current
holdings.
They were to
later learn that management voted through major constitutional changes to
Ecolibrium without their knowledge, ignoring their rights to vote.
Ms Jesani
sued, demanding the consortium be bought out at a price of $6.21 per share,
valuing the company at ten million dollars.
If successful, Ms Jesani would receive $1.04 million.
She said
this was the value management put on the company prior to what she claimed was
oppressive behaviour subsequently driving Ecolibrium into the ground.
The figure
of ten million dollars was derived from management’s draft 2020 valuation of
Ecolibrium intended to support a further capital injection from venture
capitalists, a capital injection being proposed at a time when Ms Jesani and
the consortium were discussing possibility of having their shares bought out.
No capital
injection and no share buyout eventuated.
Giving
evidence in the High Court, a valuer said no value could be ascribed to the
company as at 2020 using normal valuation principles: no valuation could be
assessed based on future earnings (there were no immediate prospects of future
earnings and Ecolibrium was currently suffering substantial negative
cashflows); and an assets-based valuation was not appropriate (product
development was still only work in progress with commercial viability not yet
established).
Raising
venture capital for a start-up company is a back-to-front process: assumptions
are made as to what a business might be worth in the future to estimate
a future exit value on listing or sale, then working backwards to fix a share
price to achieve the venture capitalists target return rate.
Venture
capital investors realise most investments will fail, written off. They spread their investments across multiple
business opportunities. If only ten per
cent of investments prove profitable, losses might be recovered with overall
returns potentially proving handsome.
Ecolibrium
management’s 2020 ten million dollar valuation was more a pie-in-the sky
estimate of future value than a then current valuation of their company.
Not
surprising, management did not respond to the consortium’s request to be bought
out at a share price based on this ten million dollar valuation.
In the High
Court, Justice Robinson ruled circumstances in which Ecolibrium management
ignored the consortium’s voting rights did amount to Companies Act ‘oppressive
behaviour.’
No useful
remedy is available, he said.
Ecolibrium
is in no position to buy them out, certainly not at $6.21 a share; it is
insolvent.
Majority
shareholders responsible for any ‘oppressive behaviour’ could not be required
to buy their shares; valueless now that the company is in liquidation insolvent.
At best,
Ecolibrium should have been put into liquidation in 2020, two years earlier than
it was, he said. Whatever value could be
extracted from company assets at that time could then have been distributed
amongst all shareholders, including the consortium.
Jesani v.
Ford – High Court (11.06.26)
26.176